First report of effective and feasible treatment of multifocal lymphangiomatosis (Gorham-Stout) with bevacizumab in a child

Annals of Oncology

Volumn 21, Issue 8, 2010, Pages 1733-1734

  Grunewald, T G P ^a   Damke, L ^a   Maschan, M ^b   Petrova, U ^c   Surianinova, O ^d   Esipenko, A ^d   Konovalov, D ^b   Behrends, U ^a   Schiessl, J ^e   Wortler K ^a   Burdach, S ^a   von Luettichau, I ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Federal Clinical Research Center for Paediatric Haematology Oncology and Immunology   (Russian Federation)

^c Russian Children's Clinical Hospital   (Russian Federation)

^d Yaroslavl Regional Clinical Hospital   (Russian Federation)

^e Klinikum Schwabing   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; IMATINIB; PEGINTERFERON ALPHA2B; STEROID;

ADD ON THERAPY; BONE BIOPSY; CASE REPORT; CHILD; CLAVICLE; CLAVICLE FRACTURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; FEASIBILITY STUDY; GORHAM STOUT DISEASE; HEPATOSPLENOMEGALY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LETTER; LYMPHANGIOMATOSIS; MALE; OSTEOLYSIS; PLEURA EFFUSION; PRESCHOOL CHILD; PRIORITY JOURNAL; RIB; STERNUM; STEROID THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77955241423     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq331     Document Type: Letter

References (5)

1. Gorham LW, Wright AW, Shultz HH, Maxon FC Jr. Disappearing bones: a rare form of massive osteolysis; report of two cases, one with autopsy findings. Am J Med 1954; 17: 674-682.
2. Ozeki M, Funato M, Kanda K et al. Clinical improvement of diffuse lymphangiomatosis with pegylated interferon alfa-2b therapy: case report and review of the literature. Pediatr Hematol Oncol 2007; 24: 513-524.
3. Colucci S, Taraboletti G, Primo L et al. Gorham-Stout syndrome: a monocytemediated cytokine propelled disease. J Bone Miner Res 2006; 21: 207-218.
4. Dupond JL, Bermont L, Runge M, de Billy M. Plasma VEGF determination in disseminated lymphangiomatosis-Gorham-Stout syndrome: a marker of activity? A case report with a 5-year follow-up. Bone 2010; 46(3): 873-876.
5. Glade Bender JL, Adamson PC, Reid JM et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 2008; 26: 399-405.